Adaptive Biotechnologies ADPT Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$59.46M+62.7% | -$159.6M+29.2% | -$225.3M-12.4% | -$200.37M+6.4% | ||
| $16.13M-8.1% | $17.55M-14.5% | $20.53M+6.8% | $19.22M+56.9% | ||
| $51.48M-4.0% | $53.61M-14.8% | $62.91M+13.4% | $55.48M+28.3% | ||
| -$48.04M+49.5% | -$95.21M+39.1% | -$156.32M+15.0% | -$183.95M+4.6% | ||
| $2.96M-19.2% | $3.66M-65.7% | $10.7M-34.6% | $16.35M-73.5% | ||
| —— | $77.79M-40.0% | $129.65M— | —— | ||
| $30.4M+12,515% | $241K-89.3% | $2.25M-98.3% | $132.27M+387% | ||
| $22.37M— | —— | -$24.43M+49.9% | -$48.78M-412% | ||
| -$50.36M+49.1% | -$98.88M+40.8% | -$167.02M+16.6% | -$200.29M+21.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Adaptive Biotechnologies generate?
- Adaptive Biotechnologies (ADPT) generated -$29.1M in operating cash flow over the trailing twelve months.
- What is Adaptive Biotechnologies's free cash flow?
- After $2.5M of capital expenditures, Adaptive Biotechnologies's free cash flow was -$31.0M over the trailing twelve months, up 65.1% year over year.
- Where does Adaptive Biotechnologies's cash flow data come from?
- Every line is extracted from Adaptive Biotechnologies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
